Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
Clinical trial update reporting long-term usage results for Xtandi (enzalutamide) in castration-resistant prostate cancer.
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy [Phase 2]
Phase 2 study updating safety observations of enzalutamide in men with progressive castration-resistant prostate cancer previously treated w…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects [Phase 2]
Phase 2 clinical trial of pembrolizumab in metastatic castration-resistant prostate cancer, with or without DNA damage repair defects; the s…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)
This is an observational cohort study update for castration-resistant prostate cancer, including metastatic cases, registered as NCT02380274…
-
CLINICAL_TRIALS trial_result · 2024-11-08Clinical Trial Update: Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity of a Thorium-227 labeled antibody-chelator conjugat…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 results for onvansertib in combination with abiraterone and prednisone in adults with metastatic castration-resistant prostate cance…
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics [Phase 1]
A Phase 1 study evaluating HC-1119 single-dose pharmacokinetics and the effect of food on its pharmacokinetics in metastatic castration-resi…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Checkpoint Inhibitors and SBRT for MCRPC [Phase 2]
A Phase 2 trial evaluating checkpoint inhibitors in combination with stereotactic body radiotherapy for metastatic castration-resistant pros…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer [Phase 2]
This update reports Phase 2 results for the diagnostic imaging agent 68Ga-PSMA-11 PET in diagnosing metastatic castration-resistant prostate…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC [Phase 1, Phase 2]
Completed Phase 1/2 dose-escalation and efficacy study evaluating LAE001 with prednisone and afuresertib in metastatic castration-resistant …
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer [Phase 1]
A Phase 1 trial evaluating the combination of docetaxel and cirmtuzumab in metastatic castration-resistant prostate cancer has been terminat…
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer-sponsored head-to-head trial in chemotherapy-naïve metastatic castration-resistant prostate cancer comparing enzalutamide to abirater…
-
CLINICAL_TRIALS trial_result · 2024-09-26Clinical Trial Update: Combination Study of AZD5069 and Enzalutamide. [Phase 1, Phase 2]
A phase 1/2 combination trial of AZD5069 with Enzalutamide in metastatic castration-resistant prostate cancer was terminated.
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Addition of Opaganib to Androgen Antagonists in Patients With mCRPC [Phase 2]
Phase 2 trial results evaluating the addition of opaganib to androgen antagonists in patients with metastatic castration-resistant prostate …
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating AsiDNA in combination with Olaparib in participants with recurrent solid tumors has completed; the stu…
-
CLINICAL_TRIALS trial_result · 2024-09-03Clinical Trial Update: Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer [Phase 1]
This update reports the completion of a Phase 1 study of TAS3681 in metastatic castration-resistant prostate cancer.
-
CLINICAL_TRIALS trial_result · 2024-08-29Clinical Trial Update: Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) [Phase 2]
Phase 2 study of ODX (Osteodex) in metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors [Phase 1]
Phase 1 study evaluating the safety, pharmacokinetics, and preliminary efficacy of the oral SM08502 with hormonal therapy or chemotherapy in…
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC [Phase 1]
An open-label Phase 1b dose-escalation trial of a micellar docetaxel formulation in metastatic castration-resistant prostate cancer has been…
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib [Phase 2]
Phase 2 clinical trial update assessing bone response in metastatic castration-resistant prostate cancer patients treated with cabozantinib.
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: The Safety and Dosimetry Study of 177Lu-LNC1003 Injection [Phase 1]
Phase 1 safety and dosimetry study of the radiopharmaceutical 177Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer [NA]
This clinical trial update reports the completion of a study examining a combined exercise and dietary advice program for men with castratio…
-
CLINICAL_TRIALS trial_result · 2024-07-17Clinical Trial Update: Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
A completed real-world study in Taiwan assessing the safety profile and how Radium-223 dichloride behaves in routine clinical practice for c…
-
CLINICAL_TRIALS trial_result · 2024-07-16Clinical Trial Update: ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating ESK981 in combination with Nivolumab for metastatic castration-resistant prostate cancer was terminated; results we…
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer [Phase 2]
Open-label Phase 2 study of tomivosertib (eFT508) in advanced castration-resistant prostate cancer has been terminated with results posted.